undamentalytics Newsletter
Sign in

Procept Biorobotics Corp (PRCT) stock

Add to watchlist

Add holding +

NASDAQ: PRCT Nasdaq Health Care Equipment Next results ~November 4, 2026

C Fundamentals grade

Procept Biorobotics Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$9.0

Valuation models combined (2)

Base case. Range ~$8.4–$10. Weighted average of 2 models (forward price-to-sales vs peers, revenue-to-maturity model).

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Procept Biorobotics Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 3 selling8 purchases and 14 sales by directors and officers, last 12 monthsInsider trades
  • Funds141 adding, 102 cuttingOf 42 active managers that changed their stake, 25 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Procept Biorobotics files

Where Procept Biorobotics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $337m, up 22.7% on a year earlier, slower than the 29.3% growth a quarter earlier. That growth ranks 11 of 58 among the health care equipment companies we cover. Free-cash-flow margin rose to -25.2% from -32.5% a year earlier. The diluted share count is up 4.2% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 5 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $8.78 a share, against a share price of $20.19.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Procept Biorobotics Corp's trailing-twelve-month revenue grew 22.7% year on year, with a free-cash-flow margin of -25.2%. Where it lags: days sales outstanding of 116 days ranks 113 of 118 health care equipment companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 22.7% (-6.6pp vs the prior quarter), the 9th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 22.7% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.2bn.

Things to watch

  • Results due soon. Results are expected around 3 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 6.6 points lower than a quarter earlier.
  • Loss-making. Operating margin is -33.9%: costs exceed revenue.
  • Burning cash. Free cash flow was -25.2% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 15.7% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 4.2% in a year.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.47 against an average estimate of -$0.45: missed by 3.7%
Revenue
$94m, up 19.3% on a year earlier
Share reaction
+5.2% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$0.39

Procept Biorobotics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.3%
  • 1 week-2.0%
  • 1 month+13.3%
  • This year-38.2%
  • 1 year-42.9%
  • 5 years-56.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$337M
Operating margin
-33.9%
Net margin
-32.5%
EPS (TTM, diluted)
$-1.95

Growth

Revenue growth
+22.7%
Change in growth rate
−6.6 pts
Share count change
+4.2%

Cash

Free cash flow (TTM)
-$84.9M
FCF margin
-25.2%
Stock pay % of revenue
15.7%

Earnings

Last results
August 4, 2026
Next results (est.)
November 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Agreement
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Procept Biorobotics Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Procept Biorobotics Corp as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.95 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$3.1 ~$1.9–$4.2 Left out: out of range vs price (0.16x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$10 ~$11–$39 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$8.4 ~$6.4–$11 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.0 ~$8.4–$10 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Procept Biorobotics Corp with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$25.01$41.54$41.91$80.52$31.46$19.44
Market value$412m$1.8bn$2.0bn$4.2bn$1.7bn$1.1bn
+ Net debt (− = net cash)−$254m−$170m−$205m−$282m−$235m−$176m
Enterprise value$158m$1.7bn$1.8bn$3.9bn$1.5bn$919m
Multiples
Price / sales 12.0x24.6x14.5x18.7x5.7x3.2x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

25 /100

Weak moat

How hard Procept Biorobotics's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -13.6% of total assets over 5 years.

  • Pricing power 10 / 20

    Gross margin has been a median 52.9%, moving by 9.6 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -80.8%; its worst year was -232.0%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -61.9% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $101m and EPS of −$0.39 (range −$0.42 to −$0.34) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.68 +2% $395m +28%
Next −$1.17 +30% $476m +21%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +8.8% on 90 days ago. In the last 30 days, 0 analysts raised Procept Biorobotics Corp's forecast and 10 cut it.

Consensus EPS forecast Procept Biorobotics Corp, last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.55 Current fiscal year, 60 days ago: −$1.68 Current fiscal year, 30 days ago: −$1.68 Current fiscal year, 7 days ago: −$1.68 Current fiscal year, Now: −$1.68 −$1.68 Next fiscal year, 90 days ago: −$0.89 Next fiscal year, 60 days ago: −$1.15 Next fiscal year, 30 days ago: −$1.15 Next fiscal year, 7 days ago: −$1.17 Next fiscal year, Now: −$1.17 −$1.17

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.55−$0.89
60 days ago −$1.68−$1.15
30 days ago −$1.68−$1.15
7 days ago −$1.68−$1.17
Now −$1.68−$1.17

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.45 −$0.47 −3.7%
Mar 2026 −$0.56 −$0.56 +0.9%
Dec 2025 −$0.32 −$0.53 −64.1%
Sept 2025 −$0.42 −$0.38 +9.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

15 analysts, Oct 2026
Buy533%
Hold960%
Sell17%

Monthly trend

  1. Oct 202623915
  2. Sep 2026139114
  3. Aug 2026139114
  4. Jul 2026157114

Counts of recommendations published by analysts covering Procept Biorobotics Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.5%
of tradable shares
Days to cover
5.27
at average volume
Short interest, 1 month
+1%
to October 15, 2026
Held by institutions
98%
of shares
Held by insiders
3.5%
of shares
Employees
888
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −42.9%

$34.03 on October 31, 2025 to $19.44

ThenNowEffect
Revenue (last 12 months) $275m $337m +22.7%
P/S multiple 6.7x 3.2x −51.5%
Share count 54m 56m −4.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −42.7%

$33.91 on November 3, 2023 to $19.44

ThenNowEffect
Revenue (last 12 months) $102m $337m +231.9%
P/S multiple 15.0x 3.2x −78.3%
Share count 45m 56m −20.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
PRCT+66%+1%+92%−61%−38%
Industry peers (median)−37%−9%−20%−16%−13%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
PRCT67%42%83%8%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
PRCT−34%−40%−21%−69%−52%
S&P 500−25%−10%−8%−19%−9%

Worst fall since September 15, 2021: 83% from December 4, 2024 to July 24, 2026. Getting back needed a 496% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$16.69 – $36.10
From 52-week high
−46.1%
vs 50-day average
+0.4%
vs 200-day average
−16.4%
Volatility (1 year)
65%
Beta vs S&P 500
0.74

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±11.2%
After a week
4 up, 8 down
typical move ±11.9%
After a month
7 up, 5 down
typical move ±16.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +5.2% +1.6% +24.5% +19.5%
April 29, 2026 +4.4% +1.0% +7.7% +14.3%
February 25, 2026 −13.3% +0.3% −2.6% −8.0%
November 4, 2025 −8.4% −0.8% −9.2% +2.7%
August 6, 2025 −17.7% +0.7% −16.1% −15.5%
July 25, 2025 −7.8% +0.4% −14.8% −33.0%
April 24, 2025 −5.8% +2.8% −5.1% +3.0%
February 25, 2025 +4.5% −0.4% −0.3% −4.3%
October 28, 2024 +40.6% +0.5% +41.2% +44.4%
August 1, 2024 −9.4% −3.3% −2.3% +24.8%
May 1, 2024 +16.5% +0.6% +13.9% +25.3%
February 27, 2024 +1.1% +0.1% −5.0% 0.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Procept Biorobotics Corp in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Procept Biorobotics Corp
$0 $100M $200M $300M $400M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $116.4M Revenue (TTM), FY23 Q4: $136.2M Revenue (TTM), FY24 Q1: $156.3M Revenue (TTM), FY24 Q2: $176.6M Revenue (TTM), FY24 Q3: $199.8M Revenue (TTM), FY24 Q4: $224.5M Revenue (TTM), FY25 Q1: $249.1M Revenue (TTM), FY25 Q2: $275M Revenue (TTM), FY25 Q3: $299.9M Revenue (TTM), FY25 Q4: $308.1M Revenue (TTM), FY26 Q1: $322M Revenue (TTM), FY26 Q2: $337.3M $337.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $116.4M
FY23 Q4 $136.2M
FY24 Q1 $156.3M
FY24 Q2 $176.6M
FY24 Q3 $199.8M
FY24 Q4 $224.5M
FY25 Q1 $249.1M
FY25 Q2 $275M
FY25 Q3 $299.9M
FY25 Q4 $308.1M
FY26 Q1 $322M
FY26 Q2 $337.3M
Revenue growth, TTM YoY Procept Biorobotics Corp
0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 89.6% Revenue growth, TTM YoY, FY23 Q4: 81.6% Revenue growth, TTM YoY, FY24 Q1: 83.4% Revenue growth, TTM YoY, FY24 Q2: 73.7% Revenue growth, TTM YoY, FY24 Q3: 71.7% Revenue growth, TTM YoY, FY24 Q4: 64.8% Revenue growth, TTM YoY, FY25 Q1: 59.4% Revenue growth, TTM YoY, FY25 Q2: 55.7% Revenue growth, TTM YoY, FY25 Q3: 50.1% Revenue growth, TTM YoY, FY25 Q4: 37.2% Revenue growth, TTM YoY, FY26 Q1: 29.3% Revenue growth, TTM YoY, FY26 Q2: 22.7% 22.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 89.6%
FY23 Q4 81.6%
FY24 Q1 83.4%
FY24 Q2 73.7%
FY24 Q3 71.7%
FY24 Q4 64.8%
FY25 Q1 59.4%
FY25 Q2 55.7%
FY25 Q3 50.1%
FY25 Q4 37.2%
FY26 Q1 29.3%
FY26 Q2 22.7%
Operating margin (TTM) Procept Biorobotics Corp
-100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -89.9% Operating margin (TTM), FY23 Q4: -80.2% Operating margin (TTM), FY24 Q1: -69.4% Operating margin (TTM), FY24 Q2: -62.1% Operating margin (TTM), FY24 Q3: -53.3% Operating margin (TTM), FY24 Q4: -43.0% Operating margin (TTM), FY25 Q1: -38.7% Operating margin (TTM), FY25 Q2: -33.4% Operating margin (TTM), FY25 Q3: -30.9% Operating margin (TTM), FY25 Q4: -33.7% Operating margin (TTM), FY26 Q1: -33.9% Operating margin (TTM), FY26 Q2: -33.9% -33.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -89.9%
FY23 Q4 -80.2%
FY24 Q1 -69.4%
FY24 Q2 -62.1%
FY24 Q3 -53.3%
FY24 Q4 -43.0%
FY25 Q1 -38.7%
FY25 Q2 -33.4%
FY25 Q3 -30.9%
FY25 Q4 -33.7%
FY26 Q1 -33.9%
FY26 Q2 -33.9%
FCF margin (TTM) Procept Biorobotics Corp
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -108.0% FCF margin (TTM), FY23 Q4: -97.8% FCF margin (TTM), FY24 Q1: -80.7% FCF margin (TTM), FY24 Q2: -61.9% FCF margin (TTM), FY24 Q3: -51.8% FCF margin (TTM), FY24 Q4: -46.2% FCF margin (TTM), FY25 Q1: -35.4% FCF margin (TTM), FY25 Q2: -32.5% FCF margin (TTM), FY25 Q3: -26.6% FCF margin (TTM), FY25 Q4: -18.9% FCF margin (TTM), FY26 Q1: -25.0% FCF margin (TTM), FY26 Q2: -25.2% -25.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -108.0%
FY23 Q4 -97.8%
FY24 Q1 -80.7%
FY24 Q2 -61.9%
FY24 Q3 -51.8%
FY24 Q4 -46.2%
FY25 Q1 -35.4%
FY25 Q2 -32.5%
FY25 Q3 -26.6%
FY25 Q4 -18.9%
FY26 Q1 -25.0%
FY26 Q2 -25.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 8 34 75 136 224 308 337
Gross profit −1 16 37 71 137 196 217
EBITDA −45 −51 −78 −105 −91 −97 −107
Operating income −48 −54 −81 −109 −97 −104 −114
Net income −53 −60 −87 −106 −91 −96 −110
Diluted EPS −$14.47 −$3.63 −$1.96 −$2.24 −$1.75 −$1.72 −$1.95
Growth (year on year)
Revenue — +346.7% +117.6% +81.6% +64.8% +37.2% +22.7%
Margins
Gross margin −16.3% 46.0% 49.4% 52.2% 61.1% 63.7% 64.2%
EBITDA margin −582.4% −147.5% −103.8% −77.4% −40.7% −31.6% −31.8%
Operating margin −619.4% −157.1% −107.6% −80.2% −43.0% −33.7% −33.9%
Net margin −687.0% −173.6% −116.2% −77.8% −40.7% −31.0% −32.5%
Free-cash-flow margin −629.5% −168.0% −110.7% −97.8% −46.2% −18.9% −25.2%
Cash flow
Cash from operations −48 −57 −80 −108 −99 −49 −74
Capital spending 0 1 3 25 4 9 11
Free cash flow −49 −58 −83 −133 −104 −58 −85
Stock-based pay 2 4 10 19 32 48 53
Free cash flow after stock pay −51 −62 −93 −152 −135 −106 −138
Balance sheet
Cash 100 304 222 257 334 287 228
Total debt 50 50 52 52 52 52 52
Net debt (negative = net cash) −50 −254 −170 −205 −282 −235 −176
Diluted shares 4m 16m 44m 47m 52m 56m 56m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

5 of 7 checks passed · June 30, 2026
What it owns · $479m
Short-term assets $420mLonger-term assets $59m
What it owes, and who funded it · $479m
Short-term liabilities $64mLonger-term liabilities $75mShareholders' equity $340m
  • Short-term assets cover short-term liabilities $420m of assets due within a year against $64m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $420m short-term assets against $75m of longer-dated liabilities.
  • More cash than debt $228m of cash against $52m of debt.
  • Debt below 40% of shareholders' equity Debt is 15% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 19% to 15% over five years.
  • A year's operating cash flow covers at least 20% of debt −$74m of operating cash flow against $52m of debt.
  • Operating profit covers interest at least five times over Operating income of −$114m against $3m of interest.

From Procept Biorobotics Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+4.2%
year over year
R&D spending
23.4%
of revenue
Sales & admin spending
74.7%
of revenue
Days sales outstanding
116 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated PRCT STAA ANGO INGN TCMD INMD Median
Revenue, last 12 months $337m $340m $325m $354m $356m $370m $99m
Revenue growth, last 12 months 22.7% 51.3% 8.2% 3.2% 14.4% −6.2% 9.2%
Revenue growth, 3-year average 49.2% 9.2% −1.1% 0.5% 9.6% — 13.5%
Revenue growth, latest quarter 19.3% 111.0% 6.9% 3.0% 7.1% — 10.2%
Gross margin 64.2% 76.6% 55.7% 44.5% 77.0% 78.5% 61.2%
Operating margin −33.9% 4.0% −11.2% −8.7% 9.4% 23.0% −8.5%
Operating margin, 3-year average −43.1% −12.3% −35.3% −16.2% 8.1% 28.9% −17.9%
Net margin −32.5% 1.1% −10.1% −6.9% 6.7% 25.3% −12.0%
Cash from operations / revenue −22.0% −1.0% 1.1% −0.7% 9.0% 23.0% −1.9%
Free-cash-flow margin −25.2% −2.0% 0.4% −1.4% 8.1% 22.7% −3.9%
Free-cash-flow margin, 3-year average −39.8% −5.8% −3.8% −1.8% 11.6% 32.8% −7.0%
Stock pay / revenue 15.7% 8.3% 4.3% 2.1% 2.5% 3.0% 6.1%
Change in share count 4.2% 2.6% 1.8% 8.9% −1.7% −18.8% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 22.7% 9.1% 36 of 129
Change in growth rate Growth -6.6pp -0.6pp 105 of 129
Gross margin Profitability 64.2% 61.9% 55 of 123
Operating margin Profitability -33.9% -8.3% 82 of 132
Net margin Profitability -32.5% -12.0% 79 of 133
Free-cash-flow margin Cash generation -25.2% -3.4% 83 of 128
Stock pay as % of revenue Cash generation 15.7% 6.1% 90 of 123
Long-term debt as % of assets Balance sheet 10.8% 24.2% 26 of 87
Change in share count Balance sheet 4.2% 3.3% 67 of 115
Days sales outstanding Balance sheet 116 days 57 days 113 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
United States $270M 87.8% ▲ 34.9%
Outside the US $37.7M 12.2% ▲ 56.8%

From Procept Biorobotics Corp's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.2B
Institutions reporting
254
Shares held vs prior quarter
▼ 1.8%
Positions opened / closed
35 / 36

Top buyers and sellers, Q2 2026: 141 institutions bought and 102 sold ; the biggest buyer was Federated Hermes, Inc (+1.1M shares) and the biggest seller Mackenzie Financial Corp (−1.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $110M 4.9M 8.9% ▲ 11.6%
T. Rowe Price Investment Management, Inc. $73.7M 3.3M 6.0% ▼ 0.2%
BNP Paribas Asset Management Holding S.A. $63.8M 2.8M 5.1% ▼ 8.6%
Vanguard Portfolio Management LLC $57.1M 2.5M 4.6% ▲ 4.4%
Vanguard Capital Management LLC $55.6M 2.5M 4.5% ▲ 2.6%
Chicago Capital, LLC $46.8M 2.1M 3.8% ▼ 4.0%
State Street Corp $36.5M 1.6M 2.9% ▲ 5.7%
Geode Capital Management, LLC $33.5M 1.5M 2.7% ▲ 8.8%
FMR LLC $32.6M 1.4M 2.6% ▼ 1.2%
Price T Rowe Associates Inc $30.1M 1.3M 2.4% ▲ 119.9%
Wellington Management Group LLP $28.8M 1.3M 2.3% ▲ 47.9%
Federated Hermes, Inc. $28.3M 1.3M 2.3% ▲ 618.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Procept Biorobotics Corp's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $11M 8 trades by 2 insiders, last 12 months Insider sales History → $623,819 14 trades by 3 insiders · 36% under pre-set plans
Net ▲ $10.4M net buying
Insider Date Trade Shares Price Value
Waters Kevin EVP, CFO September 9, 2026 Sell 373 $20.95 $7,814
Templin Barry L EVP, Chief Technology Officer September 9, 2026 Sell 373 $20.95 $7,814
Nouri Alaleh EVP, CLO, CORP. SEC. September 9, 2026 Sell 297 $20.95 $6,222
Wood Larry L President, CEO August 7, 2026 Buy 23,900 $20.85 $498,315
Templin Barry L EVP, Chief Technology Officer June 8, 2026 Sell 358 $28.48 $10,196
Waters Kevin EVP, CFO June 8, 2026 Sell 357 $28.48 $10,167
Nouri Alaleh EVP, CLO, CORP. SEC. June 8, 2026 Sell 285 $28.48 $8,117
Nouri Alaleh EVP, CLO, CORP. SEC. March 19, 2026 Sell pre-set plan 2,332 $26.15 $60,982
Nouri Alaleh EVP, CLO, CORP. SEC. March 19, 2026 Sell pre-set plan 3,031 $25.82 $78,260
Waters Kevin EVP, CFO March 17, 2026 Sell 706 $28.15 $19,874
Nouri Alaleh EVP, CLO, CORP. SEC. March 17, 2026 Sell 304 $28.15 $8,558
Nouri Alaleh EVP, CLO, CORP. SEC. March 10, 2026 Sell pre-set plan 3,098 $25.60 $79,309

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 3, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • April 29, 2026
  • February 25, 2026
  • November 4, 2025
  • August 6, 2025
  • July 25, 2025

Recent SEC filings

Data status

When each part of this page on Procept Biorobotics Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Procept Biorobotics Corp in brief

What does Procept Biorobotics Corp do?
Procept Biorobotics Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Procept Biorobotics Corp's stock ticker?
Procept Biorobotics Corp trades under the ticker PRCT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Procept Biorobotics Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Procept Biorobotics Corp reported revenue of $337M, 22.7% higher than a year earlier, according to its SEC filings.
What is Procept Biorobotics Corp's free cash flow?
Procept Biorobotics Corp's free-cash-flow margin is -25.2% of revenue over the trailing twelve months, ranking 83 of the 128 health care equipment companies we cover.
Who are Procept Biorobotics Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., T. Rowe Price Investment Management, Inc. and BNP Paribas Asset Management Holding S.A. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Procept Biorobotics Corp's market cap?
On November 2, 2026, Procept Biorobotics Corp's market capitalisation was about $1.1B and net debt of -$176M. Market figures come from third-party market data and may be delayed.
How much debt does Procept Biorobotics Corp have?
Procept Biorobotics Corp's debt-to-equity ratio is 15.2%, from its latest balance sheet (18.7% five years earlier). The financial health section below sets out its other solvency checks.
Who are Procept Biorobotics Corp's competitors?
In our Health Care Equipment peer group, the companies closest to Procept Biorobotics Corp are Staar Surgical Co, Angiodynamics Inc, Inogen Inc, Tactile Systems Technology Inc and Inmode Ltd. The side-by-side comparison below sets their revenue, margins and growth against Procept Biorobotics Corp's.
Are insiders buying or selling Procept Biorobotics Corp stock?
Over the last 12 months, Procept Biorobotics Corp's directors and officers reported 8 open-market purchases and 14 sales on Form 4. The insider trading page charts every trade.
When is Procept Biorobotics Corp's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Procept Biorobotics Corp announces its own schedule.